Home
>
US Stocks
>
Pfizer Inc.

Pfizer Inc. (PFE)

$38.02

[object Object]

([object Object]%)▲

Market is closed - opens 7 PM, 02 Jun 2023
star icon

Pfizer Inc is a multinational pharmaceutical corporation that produces and develops a wide range of innovative health products.

Insights on Pfizer Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 24.29B → 18.28B (in $), with an average decrease of 24.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 4.99B → 5.54B (in $), with an average increase of 9.9% per quarter

  • Vs PG

    In the last 1 year, Pfizer Inc. has experienced a drawdown of -27.8%, however Procter & Gamble Co. resisted the overall trend and outperformed by 25.6%

  • Vs PG

    In the last 3 years, Procter & Gamble Co. has given 21.9% return, outperforming this stock by 16.8%

Performance

  • $37.70
    $38.20
    $38.02
    downward going graph

    0.83%

    Downside

    Day's Volatility :1.29%

    Upside

    0.46%

    downward going graph
  • $36.17
    $53.85
    $38.02
    downward going graph

    4.87%

    Downside

    52 Weeks Volatility :32.83%

    Upside

    29.4%

    downward going graph

Returns

PeriodPfizer Inc.Sector (Health Care)S&P500
3 Months
-6.4%
0.7%
6.0%
6 Months
-25.32%
-7.9%
3.7%
1 Year
-27.83%
-2.0%
1.1%
3 Years
5.14%
25.4%
37.0%

Highlights

Market Capitalization
214.6B
Book Value
$17.89
Dividend Share
1.61
Dividend Yield
4.43%
Earnings Per Share (EPS)
5.07
PE Ratio
7.5
PEG Ratio
1.17
Wall Street Target Price
47.06
Profit Margin
31.25%
Operating Margin TTM
37.87%
Return On Assets TTM
11.59%
Return On Equity TTM
31.62%
Revenue TTM
93.0B
Revenue Per Share TTM
16.56
Quarterly Revenue Growth YOY
-28.799999999999997%
Gross Profit TTM
66.2B
EBITDA
40.5B
Diluted Eps TTM
5.07
Quarterly Earnings Growth YOY
-0.29
EPS Estimate Current Year
3.35
EPS Estimate Next Year
3.5
EPS Estimate Current Quarter
0.98
EPS Estimate Next Quarter
0.7

Analyst Recommendation

Buy
    51%Buy
    48%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Pfizer Inc.(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
14
Hold
14
15
15
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 23.78%

Current $38.02
Target $47.06

Company Financials

FY17Y/Y Change
Revenue
52.5B
↓ 0.53%
Net Income
21.3B
↑ 195.33%
Net Profit Margin
40.55%
↑ 26.89%
FY18Y/Y Change
Revenue
53.6B
↑ 2.1%
Net Income
11.2B
↓ 47.66%
Net Profit Margin
20.79%
↓ 19.76%
FY19Y/Y Change
Revenue
51.8B
↓ 3.54%
Net Income
16.3B
↑ 45.91%
Net Profit Margin
31.45%
↑ 10.66%
FY20Y/Y Change
Revenue
41.9B
↓ 19.02%
Net Income
9.6B
↓ 40.91%
Net Profit Margin
22.95%
↓ 8.5%
FY21Y/Y Change
Revenue
81.3B
↑ 93.97%
Net Income
22.0B
↑ 128.57%
Net Profit Margin
27.04%
↑ 4.09%
FY22Y/Y Change
Revenue
100.3B
↑ 23.43%
Net Income
31.4B
↑ 42.74%
Net Profit Margin
31.27%
↑ 4.23%
Q4 FY21Q/Q Change
Revenue
23.6B
↓ 1.91%
Net Income
3.4B
↓ 58.35%
Net Profit Margin
14.36%
↓ 19.45%
Q1 FY22Q/Q Change
Revenue
25.7B
↑ 8.57%
Net Income
7.9B
↑ 131.77%
Net Profit Margin
30.65%
↑ 16.29%
Q2 FY22Q/Q Change
Revenue
27.7B
↑ 8.11%
Net Income
9.9B
↑ 25.97%
Net Profit Margin
35.71%
↑ 5.06%
Q3 FY22Q/Q Change
Revenue
22.6B
↓ 18.4%
Net Income
8.6B
↓ 13.1%
Net Profit Margin
38.02%
↑ 2.31%
Q4 FY22Q/Q Change
Revenue
24.3B
↑ 7.3%
Net Income
5.0B
↓ 41.97%
Net Profit Margin
20.56%
↓ 17.46%
Q1 FY23Q/Q Change
Revenue
18.3B
↓ 24.73%
Net Income
5.5B
↑ 10.97%
Net Profit Margin
30.32%
↑ 9.76%
FY17Y/Y Change
Total Assets
171.8B
↑ 0.1%
Total Liabilities
100.1B
↓ 10.41%
FY18Y/Y Change
Total Assets
159.4B
↓ 7.2%
Total Liabilities
95.7B
↓ 4.47%
FY19Y/Y Change
Total Assets
167.5B
↑ 5.06%
Total Liabilities
104.0B
↑ 8.76%
FY20Y/Y Change
Total Assets
154.2B
↓ 7.92%
Total Liabilities
90.8B
↓ 12.77%
FY21Y/Y Change
Total Assets
181.5B
↑ 17.67%
Total Liabilities
104.0B
↑ 14.61%
FY22Y/Y Change
Total Assets
197.2B
↑ 8.67%
Total Liabilities
101.3B
↓ 2.62%
Q4 FY21Q/Q Change
Total Assets
181.5B
↑ 1.28%
Total Liabilities
104.0B
↑ 0.77%
Q1 FY22Q/Q Change
Total Assets
183.8B
↑ 1.3%
Total Liabilities
101.2B
↓ 2.75%
Q2 FY22Q/Q Change
Total Assets
195.3B
↑ 6.23%
Total Liabilities
107.8B
↑ 6.59%
Q3 FY22Q/Q Change
Total Assets
195.4B
↑ 0.03%
Total Liabilities
102.5B
↓ 4.97%
Q4 FY22Q/Q Change
Total Assets
197.2B
↑ 0.95%
Total Liabilities
101.3B
↓ 1.14%
FY17Y/Y Change
Operating Cash Flow
16.5B
↑ 3.58%
Investing Cash Flow
-4.7B
↓ 39.3%
Financing Cash Flow
-13.0B
↑ 46.12%
FY18Y/Y Change
Operating Cash Flow
15.8B
↓ 3.9%
Investing Cash Flow
4.5B
↓ 195.44%
Financing Cash Flow
-20.4B
↑ 56.82%
FY19Y/Y Change
Operating Cash Flow
12.6B
↓ 20.47%
Investing Cash Flow
-3.9B
↓ 187.18%
Financing Cash Flow
-8.5B
↓ 58.49%
FY20Y/Y Change
Operating Cash Flow
14.4B
↑ 14.42%
Investing Cash Flow
-4.3B
↑ 8.26%
Financing Cash Flow
-9.6B
↑ 13.72%
FY21Y/Y Change
Operating Cash Flow
32.6B
↑ 126.2%
Investing Cash Flow
-22.5B
↑ 427.89%
Financing Cash Flow
-9.8B
↑ 1.73%
FY22Y/Y Change
Operating Cash Flow
29.3B
↓ 10.17%
Investing Cash Flow
-15.8B
↓ 30.0%
Financing Cash Flow
-14.8B
↑ 51.12%
Q4 FY21Q/Q Change
Operating Cash Flow
5.9B
↓ 45.39%
Investing Cash Flow
-2.6B
↓ 74.34%
Financing Cash Flow
-3.4B
↑ 204.36%
Q1 FY22Q/Q Change
Operating Cash Flow
6.5B
↑ 10.6%
Investing Cash Flow
567.0M
↓ 121.93%
Financing Cash Flow
-6.6B
↑ 96.3%
Q2 FY22Q/Q Change
Operating Cash Flow
8.2B
↑ 24.9%
Investing Cash Flow
-11.3B
↓ 2095.24%
Financing Cash Flow
2.5B
↓ 138.31%
Q3 FY22Q/Q Change
Operating Cash Flow
6.0B
↓ 26.88%
Investing Cash Flow
-627.0M
↓ 94.46%
Financing Cash Flow
-5.8B
↓ 328.61%
Q4 FY22Q/Q Change
Operating Cash Flow
8.6B
↑ 43.66%
Investing Cash Flow
-15.8B
↑ 2417.22%
Financing Cash Flow
-5.0B
↓ 12.95%
Q1 FY23Q/Q Change
Operating Cash Flow
1.2B
↓ 85.88%
Investing Cash Flow
3.3B
↓ 121.0%
Financing Cash Flow
-2.8B
↓ 44.75%

Technicals Summary

Sell

Neutral

Buy

Pfizer Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pfizer Inc.
Pfizer Inc.
-2.66%
-25.32%
-27.83%
5.14%
4.31%
Procter & Gamble Company, The
Procter & Gamble Company, The
-7.97%
-4.42%
-2.21%
21.94%
94.07%
Johnson & Johnson
Johnson & Johnson
-6.36%
-13.61%
-12.76%
4.24%
26.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pfizer Inc.
Pfizer Inc.
7.5
7.5
1.17
3.35
0.32
0.12
0.04
17.89
Procter & Gamble Company, The
Procter & Gamble Company, The
24.32
24.32
4.98
5.86
31.56
0.1
0.03
18.8
Johnson & Johnson
Johnson & Johnson
17.79
17.79
3.79
10.66
17.48
0.09
0.03
27.28
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pfizer Inc.
Pfizer Inc.
Buy
$214.6B
4.31%
7.5
31.25%
Procter & Gamble Company, The
Procter & Gamble Company, The
Buy
$337.5B
94.07%
24.32
17.69%
Johnson & Johnson
Johnson & Johnson
Hold
$401.2B
26.72%
17.79
13.22%

Institutional Holdings

  • Vanguard Group Inc

    9.01%

  • BlackRock Inc

    7.85%

  • State Street Corporation

    4.99%

  • Capital World Investors

    4.10%

  • Wellington Management Company LLP

    3.53%

  • Geode Capital Management, LLC

    1.94%

Corporate Announcements

  • Pfizer Inc. Dividends March,2023

    In the quarter ending March,2023. Pfizer Inc. has declared dividend of $0.41

    Read More

Company Information

“Pfizer Inc., founded in 1849 by Charles Pfizer and Charles F. Erhart, is an American Biotechnology and Pharmaceutical giant. It is currently headquartered in New York City, United States with worldwide operations and distributions. To ensure that the medicinal and vaccine requirements of every patient and individual are met, Pfizer has been adopting a rigorous and scientific approach towards its supply chain. They now have a network of 58 manufacturing sites around the world under Pfizer Global Supply (PGS). To further expand its operations in the research and pharmaceutical sphere, it entered various merger and acquisitions deals with other players including Wyeth, Pharmacia, Warner-Lambert, Innopharma, etc. Its primary focus areas include internal medicine, rare diseases, vaccines, inflammation, immunology, oncology, and anti-infectives. They have major R&D platforms in the fields of gene therapy, precision medicine, biosimilars, medicinal sciences, and maternal immunizations. Pfizer Is traded under the ticker symbol of PFE. The financials of Pfizer are as follows: While Pfizer clocked a revenue of $41.908 billion for 2020, its net income amounted to $6985 million for the same period. Pfizer has made significant contributions in the fight against Covid-19 and has been successful in the early development of the Pfizer-BioNTech Vocid-19 vaccine. In 2020, Pfizer achieved the Top Employer Certification for the 5th year in the UK. Going by the revenue, Pfizer is the 4th largest pharmaceutical company globally and the 3rd largest in terms of market capitalization. It is currently traded in NYSE and other indices, including S&P 100, S&P 500, and Russell 1000 Index. Currently Pfizer Inc. has a market cap of $214.63 Billion. It has a P.E ratio of 7.39. The shares of Pfizer Inc. are trading at $38.02. ” .

Organization
Pfizer Inc.
Employees
83000
CEO
Dr. Albert Bourla D.V.M., DVM, Ph.D.
Industry
Health Technology

Discover More

FAQs